174671-46-6

URI: https://gptkb.org/entity/174671-46-6

GPTKB entity

Predicate	Object
gptkbp:instanceOf	gptkb:chemical_compound
gptkbp:administeredBy	oral
gptkbp:approvalYear	2014
gptkbp:ATCCode	N05CM25
gptkbp:brand	gptkb:Belsomra
gptkbp:CASNumber	gptkb:174671-46-6
gptkbp:developedBy	gptkb:Merck_&_Co.
gptkbp:eliminationHalfLife	12 hours
gptkbp:excretion	urine feces
gptkbp:hasInChIKey	QOVJKBMQGXRZQQ-UHFFFAOYSA-N
gptkbp:hasMolecularFormula	C23H23ClN6O2
gptkbp:hasSMILES	CN1CCN(CC1)C(=O)C2=CC(=C(C=C2)C)N3N=CC=N3
gptkbp:hasUNII	7X9Q64V4A4
gptkbp:isApprovedDrug	true
gptkbp:IUPACName	[(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone
gptkbp:legalStatus	Rx-only (US)
gptkbp:mechanismOfAction	gptkb:orexin_receptor_antagonist
gptkbp:metabolism	gptkb:liver_(CYP3A)
gptkbp:molecularWeight	450.92 g/mol
gptkbp:name	gptkb:Suvorexant
gptkbp:pregnancyCategory	C (US)
gptkbp:PubChem_CID	CHEMBL2105758 24964624 DB09025
gptkbp:routeOfAdministration	oral
gptkbp:sideEffect	fatigue headache somnolence abnormal dreams
gptkbp:usedFor	treatment of insomnia
gptkbp:bfsParent	gptkb:tavaborole
gptkbp:bfsLayer	8
https://www.w3.org/2000/01/rdf-schema#label	174671-46-6